The data‐independent acquisition mass spectrometry (DIA‐MS) has rapidly evolved as a
powerful alternative for highly reproducible proteome profiling with a unique strength of …

Data-independent acquisition (DIA) mass spectrometry (MS) has emerged as a powerful
technology for high-throughput, accurate, and reproducible quantitative proteomics. This …

Objective Epalrestat, an aldose reductase inhibitor increases phosphomannomutase (PMM)
enzyme activity in a PMM2‐congenital disorders of glycosylation (CDG) worm model …

Facilitated by advances in the separation sciences, mass spectrometry and informatics,
glycoproteomics, the analysis of intact glycopeptides at scale, has recently matured enabling …

Data-independent acquisition (DIA) approaches provide comprehensive records of all
detectable pre-cursor and fragment ions. Here we introduce midiaPASEF, a novel DIA scan …

Abstract Phosphoglucomutase 1 (PGM1) deficiency is recognized as the third most common
N-linked congenital disorders of glycosylation (CDG) in humans. Affected individuals …

Congenital disorders of glycosylation are genetic disorders that occur due to defects in
protein and lipid glycosylation pathways. A deficiency of N‐glycanase 1, encoded by the …

The combination of short liquid chromatography (LC) gradients and data-independent
acquisition (DIA) by mass spectrometry (MS) has proven its huge potential for high …

The data-independent acquisition (DIA) performed in the latest high-resolution, high-speed
mass spectrometers offers a powerful analytical tool for biological investigations. The DIA …

Several plasma glycoproteins are clinically useful as biomarkers in a variety of diseases.
Although thousands of proteins are present in plasma,> 95% of the plasma proteome by …